Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy
- PMID: 27882192
- PMCID: PMC5108033
- DOI: 10.1021/acsmedchemlett.6b00421
Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy
References
-
- Junutula J. R.; Raab H.; Clark S.; Bhakta S.; Leipold D. D.; Weir S.; Chen Y.; Simpson M.; Tsai S. P.; Dennis M. S.; Lu Y.; Meng Y. G.; Ng C.; Yang J.; Lee C. C.; Duenas E.; Gorrell J.; Katta V.; Kim A.; McDorman K.; Flagella K.; Ross S.; Venook R.; Spencer S. D.; Wong W. L.; Lowman H. B.; Vandlen R.; Slikowski M. X.; Scheller R. H.; Polakis P.; Malllet W. Site-specific conjugation of cytotoxic drugs to antibodies substantially improves the therapeutic index. Nat. Biotechnol. 2008, 26, 925–932. 10.1038/nbt.1480. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
